Does the 42-state probe make Anthropic the safer IPO bet now?

On regulatory-risk grounds, yes — for now. Anthropic has no comparable open multistate consumer-protection action as of June 14, 2026. That doesn't mean Anthropic is risk-free (it faces its own copyright cases and the Claude Fable 5 US-only export restriction is itself a regulatory signal), but the comparison on consumer-protection exposure is one-sided right now. Long-term valuation still favors OpenAI by raw revenue and user base, so 'safer' here means risk-adjusted, not absolute.

Will OpenAI's IPO actually get delayed?

Almost certainly not. A fact-finding subpoena does not block an IPO — only an active formal complaint or criminal action does. But expect OpenAI to file an S-1 amendment within ~30 days with expanded risk disclosure, and expect roadshow questions to push back the marketing window by 2–6 weeks. The IPO timing risk widens; it doesn't disappear.

How does this change valuations for both companies?

Pre-probe consensus had OpenAI at $852B and Anthropic at $965B (private secondary markets, May 2026). After June 13, OpenAI's risk-adjusted valuation in private secondary trades has been quoted at small discounts (analysts estimate 5–12% haircut on float price), while Anthropic's IPO-window pricing has firmed. Net: the gap narrows. We'll know real numbers when both files price their offerings.

What should enterprise buyers do right now?

If you're locked into an OpenAI contract: nothing changes. If you're in active vendor selection in a regulated vertical (health, education, public sector, minors): pause final-stage OpenAI evaluations and add Anthropic and Google to your shortlist if not already there. The probe will produce specific platform policy changes within 90 days, and you want to architect against the post-probe policy, not the pre-probe one.

Quick Answer

OpenAI 42-State Probe vs Anthropic IPO Positioning (June 2026)

Published: June 14, 2026

OpenAI 42-State Probe vs Anthropic IPO Positioning (June 2026)

On June 13, 2026, 42 state attorneys general served OpenAI with a multistate consumer-protection subpoena — four days before the company’s expected IPO marketing window opens. Anthropic, racing toward its own October 2026 IPO, faces no equivalent probe. This page maps how the two companies’ regulatory positioning now compares.

Last verified: June 14, 2026

TL;DR

OpenAI: 42-state subpoena (June 13), $852B private valuation, IPO filed early June, S-1 amendment likely within 30 days, float-price risk widens.
Anthropic: No multistate consumer-protection probe, $965B private valuation, IPO targeted October 2026, Claude Fable 5 US-only restriction is the main open regulatory question.
Net: Regulatory risk gap favors Anthropic; revenue and user-base gap favors OpenAI.
Enterprise impact: Active OpenAI vendor selection in regulated verticals deserves a pause + Anthropic/Google shortlist.

Side-by-side: regulatory posture

Dimension	OpenAI (June 14, 2026)	Anthropic (June 14, 2026)
Active multistate consumer-protection probe	Yes — 42 states, served June 13	No
Active state-level lawsuit	Florida AG suit (June 2026)	None
Open wrongful-death civil suit	Yes (Canada, Q1 2026)	None
Copyright litigation	Yes (NYT, others — pre-existing)	Yes (publishers — pre-existing)
Export / national-security restrictions	None known	Claude Fable 5 US-only (export restriction on Mythos-class capabilities)
FTC active inquiry	Inactive since 2024	No
Active EU DSA / AI Act enforcement	Standard compliance only	Standard compliance only
Filed IPO documents	Yes (early June 2026)	Yes (targeting October 2026)

What the OpenAI probe actually covers

The June 13 subpoena demands records across six categories: advertising claims about safety, user engagement and retention metrics, consumer and health data, activities involving minors and seniors, deep learning model details, and internal company policies. See OpenAI Investigated by 42 State AGs: What It Means for the full breakdown.

The pattern resembles the Meta teen mental health template — fact-finding subpoena → discovered internal documents → either consent decree or per-state complaints. Time-to-resolution in comparable cases: 12–36 months.

What Anthropic faces instead

Anthropic’s main open regulatory question is the Claude Fable 5 US-only restriction. On June 9, 2026, Anthropic launched Fable 5 — its first publicly accessible Mythos-class model — but immediately restricted it to US customers following a US government restriction on Mythos-class capabilities. See Claude Fable 5 cybersecurity restrictions explained and how to switch to Claude Fable 5 in Claude Code / Cursor.

The US-only posture is a regulatory restriction — but it’s also a regulatory story. Anthropic can argue to IPO investors that it works closely with US national security, which lowers the risk that the same multistate AG dynamic OpenAI now faces will materialize.

Valuation impact

Pre-probe secondary-market quotes (early June 2026):

OpenAI: ~$852B
Anthropic: ~$965B (Anthropic was already trading above OpenAI on private secondaries — see Anthropic $965B vs OpenAI $852B valuation)

Post-probe (June 13–14):

OpenAI: Secondary quotes implied a 5–12% haircut on IPO float-price targets. The probe doesn’t change DCF much; it changes the discount rate that buy-side allocators apply.
Anthropic: IPO-window pricing firmed marginally. Same DCF, slightly tighter discount rate.

Net: the gap narrows. If OpenAI prices its IPO at a 10% discount to its pre-probe target, OpenAI floats at ~$767B and the Anthropic premium widens. If OpenAI prices at-target after fast settlement signals, the gap reverts.

What it means for the IPO timing

Milestone	OpenAI	Anthropic
S-1 filing	Early June 2026 ✅	Expected ~August 2026
Marketing window	Late June → mid-July 2026	Late September → mid-October 2026
Expected pricing	Late July 2026 (now late-July to mid-August)	Mid-October 2026
Risk-adjustment from probe	2–6 week marketing delay + amended risk disclosure	No probe-driven adjustment

The probe doesn’t kill OpenAI’s IPO. It compresses the marketing-to-pricing window and forces a richer risk section in the S-1. Securities counsel at top firms (Davis Polk, Sullivan & Cromwell) routinely run IPOs with active multistate subpoenas; the playbook is well-understood.

Enterprise buyer playbook

If you’re locked into an OpenAI contract today — change nothing. The probe doesn’t pull product features, doesn’t change SLAs, doesn’t trigger any contract clauses.

If you’re in active OpenAI vendor selection in a regulated vertical (healthcare, education, public sector, minors-facing products) — pause final-stage evaluation. The probe will produce specific platform policy changes within 90 days. You want to architect against the post-probe policy, not today’s policy. In the meantime, add Anthropic and Google to your shortlist if not already there.

If you’re an investor on private secondaries — wait for the S-1 amendment. The language OpenAI uses to scope the subpoena will signal whether this is a $50M issue or a $1B+ issue. Trading blind into the next two weeks is high-variance.

If you’re a regulated buyer of frontier models (intelligence, defense, healthcare government contractors) — Anthropic’s Fable 5 US-only positioning may be a positive selection criterion, not a negative one. This is the inverse of consumer-AI logic.

Why this comparison matters more than usual

In normal times, “which AI lab is the safer IPO bet” is mostly about ARR growth and gross margin. In June 2026, regulatory risk is suddenly a first-order variable. The 42-state probe didn’t happen to Anthropic. That asymmetry is real, it’s binary, and it’s priced.

It can flip back. Anthropic gets one bad civil suit, or the Mythos-class export-restriction conversation reopens at the federal level, and the comparison inverts. But as of June 14, 2026: OpenAI is the company carrying acute regulatory weight into its IPO window, and Anthropic is not.

Information accurate as of June 14, 2026. Regulatory situations move fast; verify before committing capital or contracts.

OpenAI 42-State Probe vs Anthropic IPO Positioning (June 2026)

TL;DR

Side-by-side: regulatory posture

What the OpenAI probe actually covers

What Anthropic faces instead

Valuation impact

What it means for the IPO timing

Enterprise buyer playbook

Why this comparison matters more than usual

Related reading